Who is sponsoring NCT05471531?

NCT05471531 is sponsored by Sinovac Biotech Co., Ltd.

What drugs are being tested in NCT05471531?

Interventions in NCT05471531: Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine, Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine.

What condition does NCT05471531 study?

NCT05471531 studies Influenza and Pneumonia.

Is NCT05471531 still recruiting?

NCT05471531 is currently completed. Last updated 25 July 2022.

Last reviewed 2022-07-25 · How we verify

NCT05471531

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

Completed Phase 4 Last updated 25 July 2022

What this trial tests

Phase 4 trial testing Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in Influenza and Pneumonia in 3,000 participants. Completed in 10 July 2022.

Timeline

13 November 2021

Primary endpoint
10 March 2022

10 July 2022

Quick facts

Lead sponsor	Sinovac Biotech Co., Ltd
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	3,000
Start date	13 November 2021
Primary completion	10 March 2022
Estimated completion	10 July 2022
Sites	4 locations across China

Drugs / interventions tested

Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine

Conditions studied

Influenza and Pneumonia — all drugs for Influenza and Pneumonia →

Sponsor

Sinovac Biotech Co., Ltd — full company profile →

Who can join

60 and older, any sex, with Influenza and Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an open-label,single center phase Ⅳ clinical trial of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine.The purpose of this study is to evaluate the safety and immunogenicity of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in the elderly aged 60 years and above.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged 60 Years and Older.
Zhu Z, Sun J, Xie Y, Lu X, et al · · 2024 · cited 2× · PMID 39204058 · DOI 10.3390/vaccines12080935
The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases.
Tang W, Lu X, Zhu Z, Yu D, et al · · 2025 · PMID 40821798 · DOI 10.3389/fimmu.2025.1624095

Verify or expand the search:

Other Sinovac Biotech Co., Ltd trials

Trials by the same sponsor.

NCT07418229 — Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine · Phase 1 · not yet recruiting
NCT07416110 — Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine · Phase 3 · not yet recruiting
NCT07055295 — Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen · Phase 3 · not yet recruiting
NCT07055893 — Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen · Phase 3 · not yet recruiting
NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05471531 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sinovac Biotech Co., Ltd
Last refreshed: 25 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05471531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing